Earnings Performance - Kiniksa Pharmaceuticals reported a quarterly loss of $0 18 per share, significantly worse than the Zacks Consensus Estimate of a loss of $0 01, representing an earnings surprise of -1,700% [1] - The company's loss per share improved from $0 20 a year ago, showing a year-over-year improvement [1] - Over the last four quarters, the company has surpassed consensus EPS estimates two times [2] Revenue Performance - Kiniksa Pharmaceuticals posted revenues of $112 21 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 1 77% [2] - This represents a significant increase from year-ago revenues of $67 05 million [2] - The company has topped consensus revenue estimates four times over the last four quarters [2] Stock Performance - Kiniksa Pharmaceuticals shares have added about 57 3% since the beginning of the year, outperforming the S&P 500's gain of 22 1% [3] - The stock's immediate price movement will depend on management's commentary on the earnings call [3] Earnings Outlook - The current consensus EPS estimate is $0 02 on $119 26 million in revenues for the coming quarter and -$0 29 on $418 02 million in revenues for the current fiscal year [7] - The estimate revisions trend for Kiniksa Pharmaceuticals is favorable, translating into a Zacks Rank 2 (Buy) [6] Industry Context - Kiniksa Pharmaceuticals belongs to the Zacks Medical - Biomedical and Genetics industry, which is currently in the top 30% of the 250 plus Zacks industries [8] - The top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1 [8] Peer Comparison - Affimed N V, another stock from the same industry, is expected to post a quarterly loss of $1 14 per share, representing a year-over-year improvement of +32 9% [9] - Affimed N V's revenues are expected to be $1 41 million, down 34 4% from the year-ago quarter [9]

Exhibit 99.1 Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution – ARCALYST (rilonacept) Q3 2024 net product revenue of $112.2 million, representing 73% year-over-year growth – – ARCALYST 2024 expected net product revenue increased to $410 - $420 million – – Life DisRPted disease awareness campaign for recurrent pericarditis launched in partnership with NHL Hall of Famer, Henrik Lundqvist, and GRAMMYAward-winning singer-songwriter, Carly Pearce – – Kiniksa exp ...

– ARCALYST® (rilonacept) Q3 2024 net product revenue of $112.2 million, representing 73% year-over-year growth –– ARCALYST 2024 expected net product revenue increased to $410 - $420 million –– Life DisRPted ™ disease awareness campaign for recurrent pericarditis launched in partnership with NHL Hall of Famer, Henrik Lundqvist, and GRAMMY® Award-winning singer-songwriter, Carly Pearce –– Kiniksa expects to remain cash flow positive on an annual basis –– Conference call and webcast scheduled for 8:30 am ET to ...

LONDON, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 29, 2024 at 8:30 a.m. Eastern Time to report its third quarter 2024 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upo ...

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it. Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate revisions, etc. - ...

Kiniksa Pharmaceuticals, Ltd. (KNSA) closed the last trading session at $24.47, gaining 1.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $34.83 indicates a 42.3% upside potential. The mean estimate comprises six short-term price targets with a standard deviation of $3.92. While the lowest estimate of $30 indicates a 22.6% increase from the current price level, the most optimist ...

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it. The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock alive. Inv ...

LONDON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the 2024 Wells Fargo Healthcare Conference on Wednesday, September 4, 2024 at 8:00 a.m. Eastern Time. A live webcast of Kiniksa's presentation will be accessible through the Investors & Media section of the company's website at www.kiniksa.com. A replay of the event will also be available on Kiniksa's website within approximately 48 hours ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades. Whi ...

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done. Our "Recent Price Strength" screen, which is created on a unique short-term trading strategy, could be pretty useful in this regard. This predefined screen makes it really easy to shortlist the stocks that have enough fundamental strength to maintain their recent up ...